Latest Data Release From Clinical Trial Suggests That Hemophilia A Gene Therapy Isn’t Far Off
source: pixabay.com

Latest Data Release From Clinical Trial Suggests That Hemophilia A Gene Therapy Isn’t Far Off

According to a story from biopharmadive.com, the race to a hemophilia A gene therapy continues to tighten following a recent release of early data from Sangamo Therapeutics and Pfizer. The…

Continue Reading Latest Data Release From Clinical Trial Suggests That Hemophilia A Gene Therapy Isn’t Far Off
The Results From This Immune Thrombocytopenia Trial are Good News for Patients
source: pixabay.com

The Results From This Immune Thrombocytopenia Trial are Good News for Patients

According to a story from ucb.com, the biopharmaceutical company UCB has recently released the final results from its phase 2 clinical trial which tested the company's investigational monoclonal antibody rozanolixizumab…

Continue Reading The Results From This Immune Thrombocytopenia Trial are Good News for Patients
A Recent Trial Found the Drug Rinvoq Can be Effective Treatment for Ankylosing Spondylitis
source: pixabay.com

A Recent Trial Found the Drug Rinvoq Can be Effective Treatment for Ankylosing Spondylitis

According to a story from Ankylosing Spondylitis News, the results of a recent phase 2/3 clinical trial indicate that the drug upadacitinib (marketed as Rinvoq) can be an effective treatment…

Continue Reading A Recent Trial Found the Drug Rinvoq Can be Effective Treatment for Ankylosing Spondylitis
Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial
source: pixabay.com

Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial

According to a story from BioPortfolio, the biopharmaceutical company Aurinia Pharmaceuticals, Inc. has recently announced positive findings from its phase 3 clinical trial of the experimental drug voclosporin, which was…

Continue Reading Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial
FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes
source: pixabay.com

FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes

According to a story from BioPortfolio, Acceleron Pharma and the Bristol-Myers Squibb Company have announced recently that the US Food and Drug Administration (FDA) will review the supplemental Biologics License…

Continue Reading FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes